Aim: To compare glycaemic control, hypoglycaemia and treatment discontinuation of insulin glargine 300 units/mL (Gla-300) and insulin degludec (IDeg) in a real-world study of insulin-naïve adults with type 2 diabetes (T2D).
| INTRODUCTION
The American Diabetes Association guidelines for adults with type 2 diabetes (T2D) recommend first-line treatment with metformin and lifestyle changes. 1 If the patient's HbA1c goal is not met within 3 months of starting metformin, a second non-insulin agent should be considered. If needed, treatment should continue to be intensified by adding further non-insulin agents or basal insulin until the individualized HbA1c target is achieved. 1 The second-generation basal insulin analogues, insulin glargine 300 units/mL (Gla-300; Toujeo; Sanofi 2 ) and insulin degludec 100 and 200 units/mL (IDeg; Tresiba; Novo Nordisk 3 ) have been available in the United States since 2015. These have more stable pharmacokinetic and pharmacodynamic profiles than the first-generation basal insulin analogue, insulin glargine 100 units/mL (Gla-100). 4, 5 Recent meta-analyses of the EDITION and BEGIN randomized controlled trials (RCTs) have
shown that Gla-300 results in significantly less anytime and nocturnal hypoglycaemia than Gla-100, while IDeg results in similar anytime and significantly less nocturnal hypoglycaemia than Gla-100. 6 The DELIVER Naive real-world observational study, which used electronic medical record (EMR) data, showed improved HbA1c control and suggested reduced hypoglycaemia with Gla-300 versus Gla-100 in insulin-naïve adults with T2D. 7 Two other real-world, observational studies (DELIVER D 8 and DELIVER D+ 9 ) compared Gla-300 and IDeg in patients with T2D who switched from first-generation basal insulin
analogues. Both studies found that Gla-300 and IDeg resulted in comparable reductions in HbA1c and similar levels of hypoglycaemia.
The recent BRIGHT trial, which randomized insulin-naïve patients with T2D to Gla-300 and IDeg, reported that both second-generation basal insulin analogues resulted in similar reductions in HbA1c and similar levels of hypoglycaemia during the whole 6-month study period, with less anytime hypoglycaemia with Gla-300 during the initial 3-month insulin titration period. 10 The objective of the DELIVER Naïve D study was to compare clinical outcomes (glycaemic control and hypoglycaemia) and treatment discontinuation in insulin-naïve adults with T2D who initiated Gla-300 or IDeg in real-world clinical practice. 
| MATERIALS AND METHODS

| Study design and data source
| Propensity score matching
To address baseline imbalances between the Gla-300 and IDeg cohorts, patients were propensity score matched 13 (1:1) based on all available baseline demographics and clinical characteristics (Table 1) apart from initial basal insulin dose (as this was only available in~33% of patients), using a greedy nearest-neighbour algorithm. This procedure selected a patient treated with Gla-300 or IDeg (depending on which prematched group had the fewest patients) and then selected the closest matched patient treated with the other basal insulin. Once a match was made, patients were not reconsidered for further matching. Next, 8-2-digit matching was performed, starting sequentially from the highest to the lowest digit match. Interaction terms applied to the propensity score analysis included calendar year and T A B L E 1 Baseline patient characteristics after propensity score matching United States geographic region, to account for possible differences in product market access and formulary changes. To assess any imbalances after matching, Χ 2 or 2-sample t-tests were performed, and standardized mean differences (SMDs) calculated. An SMD <0.10 was taken to indicate a negligible difference between cohorts. 14 
| Outcomes
All outcomes were compared between the propensity score-matched cohorts of patients who initiated Gla-300 or IDeg. HbA1c change was the reduction from the latest value during 6-month baseline to the latest value during 3-to 6-month follow-up. HbA1c target attainment
[<7% and <8% (53 and 64 mmol/mol, respectively)] was assessed using the latest value during 3-to 6-month follow-up, overall and among those without hypoglycaemia. Hypoglycaemia (ICD-9-CM/ICD-10-CM diagnoses and/or blood glucose ≤70 mg/dL) was assessed as all captured events and those associated with an inpatient or emergency department (ED) encounter.
| Statistical analysis
Categorical variables are presented as frequencies and percentages;
continuous variables as means and standard deviations (SDs). Comorbidities were used to calculate Elixhauser comorbidity indexes.
15
HbA1c reductions from baseline to follow-up were tested within each matched cohort using paired t-tests. HbA1c reductions were then compared between cohorts using a 2-sample ttest. HbA1c goal attainment between cohorts was tested using Χ 2 tests.
Hypoglycaemia outcomes (any and those associated with an inpatient/ED encounter) were assessed in two ways: an intent-totreat (ITT) approach (events during fixed 6-month follow-up) and an on-treatment (OT) approach (events until treatment discontinuation or 6-month follow-up). Treatment discontinuation was defined as: no active prescription of the basal brand patients were initiated on, for up to 45 days from the latest prescription end date; or switch to another basal insulin brand.
ITT hypoglycaemia incidences [number (%) of patients with any event(s)] were compared between cohorts using logistic regression adjusting for baseline hypoglycaemia to calculate adjusted odds ratios (aORs). ITT hypoglycaemia event rates
[events per patient per year (PPPY)] were compared between cohorts using generalized linear models adjusting for baseline hypoglycaemia to calculate least-squares mean (LSM) differences.
OT crude incidences [patients with ≥1 event per person-year (PPY) at risk (to first event)] were compared between cohorts using a proportional hazard Cox model adjusting for baseline hypoglycaemia to calculate adjusted hazard ratios (aHRs). OT hypoglycaemia event rates [events PPY at risk (to discontinuation or end of 6-month follow-up)] were compared between cohorts using Poisson regression adjusting for baseline hypoglycaemia to calculate adjusted rate ratios (aRRs).
Time-to-discontinuation of the initial basal insulin and/or initiation of a subsequently prescribed different basal insulin was analysed using a proportional hazard Cox model, adjusting for factors including baseline patient demographics and clinical characteristics. Log rank tests were conducted to compare the Gla-300 and IDeg groups' hazard functions.
| Sensitivity analyses
Sensitivity analyses for HbA1c outcomes were conducted by: 3 | RESULTS
| Study population
The patient flow diagram is shown in Figure 1 . Prior to propensity score matching, there were 1277 patients in the Gla-300 cohort and 653 in the IDeg cohort. Patients who initiated Gla-300 were significantly more likely to be older, covered by Medicare, be from the Northeast United States geographic region, have been seen by an endocrinologist for their index event, and have taken calcium channel blockers and diuretics during baseline; but significantly less likely to have used a GLP-1 RA or had an ED visit during baseline (Appendix S1).
These baseline differences were almost entirely mitigated after matching, and although differences in hyperlipidaemia between the cohorts exceeded the SMD threshold, the difference was not statistically different (SMD = 0.14; P = 0.21) ( Table 1 ). In the propensity score-matched Gla-300 and IDeg cohorts (n = 638 each), the mean ages were 59.0 and 58.9 years, respectively; 54.1% and 52.2% of patients were male; mean body mass indexes were 33.5 and Figure 2B ) and without hypoglycaemia ( Figure 2C ).
By the ITT method, overall and inpatient/ED-associated hypoglycaemia incidences ( Figure 3A ) and event rates ( Figure 3B) were similar in both cohorts. This was also the case using the OT method ( Figure 3C ).
Similar proportions of patients in the Gla-300 and IDeg cohorts discontinued therapy by the end of 6-month follow-up (29.2% vs. 32.6%, respectively; aHR 0.86; 95% CI 0.71-1.05; P = 0.14; Figure 4 ).
| Sensitivity analyses
Restricting eligibility to those who did not discontinue their basal insulin within 75 days of the index date had no impact on the mean HbA1c reductions in the Gla-300 and IDeg cohorts [− Restricting hypoglycaemia events to those identified by ICD codes or blood glucose ≤70 mg/dL captured approximately 64% and 37% of all events, respectively, and 24% and 82% of inpatient/ED-associated events, respectively. There were no significant between-cohort differences for any of the hypoglycaemia outcomes in these sensitivity analyses (Appendixes S2 and S3).
| DISCUSSION
In this large, real-world, observational study of EMRs with propensity score-matched cohorts, insulin-naïve adults with T2D who initiated Gla-300 iDeg P = 0.14 F I G U R E 4 Time to treatment discontinuation. Abbreviations: Gla-300, insulin glargine 300 units/mL; IDeg, insulin degludec Gla-300 or IDeg had comparable HbA1c reductions, HbA1c target attainments, and hypoglycaemia. This is consistent with the recent 6-month BRIGHT trial, 10 in which 929 insulin-naïve adults with uncontrolled T2D were randomized 1:1 to Gla-300 or IDeg. The BRIGHT trial authors reported comparable reductions in HbA1c and similar attainment of HbA1c targets; they also reported comparable hypoglycaemia outcomes with Gla-300 and IDeg during the whole 6-month study period. 10 Results from the current study are also in line with those from three real-world, observational studies that have compared outcomes among insulin-naïve 16 or insulin-experienced 8,9,16 adults with T2D.
The real-world, observational LIGHTNING study of EMRs (Optum Humedica database) included adults with T2D who newly initiated or switched to Gla-100, insulin detemir (IDet), Gla-300, or IDeg. 16 The LIGHTNING study reported comparable HbA1c reductions and severe hypoglycaemia event rates among propensity score-matched patients who newly initiated Gla-300 or IDeg, and among those who switched to Gla-300 or IDeg. LIGHTNING also used machine learning methodology to develop a model to predict severe hypoglycaemia rates among vulnerable subgroups of patients. Using this model, no significant differences in severe hypoglycaemia were predicted with Gla-300 versus IDeg among insulin-naïve patients or among those who switched to Gla-300 versus IDeg for patients at increased hypoglycaemic risk, those with moderate/severe renal impairment, or those aged ≥65 or ≥ 75 years. 16 In DELIVER D, 8 all patients switched from
Gla-100 to Gla-300 or IDeg, while in DELIVER D+, 9 patients switched from Gla-100 or IDet to Gla-300 or IDeg. Both studies reported similar HbA1c reductions, HbA1c target attainment, and hypoglycaemia outcomes with Gla-300 and IDeg. 8, 9 However, in contrast to the current study, the BRIGHT trial, 10 and other recent real-world studies, 8, 9, 16 the CONFIRM observational study 17 has reported contradictory results. The CONFIRM study examined the EMRs of insulin-naïve adults with T2D from the same database as the current study (Explorys; IBM Watson Health), but reported that IDeg was associated with a significantly larger mean HbA1c reduction and significantly greater "reductions in the change in the likelihood of hypoglycaemia" than Gla-300. 17 The CONFIRM find- Although the results from the current study are consistent with data from the BRIGHT trial in insulin-naïve adults with T2D 10 and the three previous real-world studies in insulin-naïve or -experienced adults with T2D, 8, 9, 17 there are some interesting differences between the insulin-naïve studies. Firstly, patients in the current study had con- ).
Although this seems counterintuitive, it is probably a result of more hypoglycaemia events being captured in the BRIGHT trial (~68% of patients had any hypoglycaemia) because of more robust ascertainment of hypoglycaemia events in the context of an RCT.
| Strengths and limitations
The real-world DELIVER Naive D study provides information that complements the results from the BRIGHT trial. 10 These results, from different study types and patient populations, provide useful information to healthcare-delivery providers and clinicians on the effectiveness of two second-generation basal insulin analogues. The strengths of this study include the application of propensity score matching, which ensured a good balance between the cohorts for the observable confounders, such as body mass index. Also, the study only included patients with complete data in the propensity scorematching process to ensure that confounding was minimized for all endpoints (HbA1c and hypoglycaemia) under analysis. Lastly, sensitivity analyses confirmed the results from the main analyses.
However, there are some limitations to note, including the retrospective design and short, variable follow-up. A variable follow-up window of 3-6 months was chosen to allow for maximum inclusion of patients while maintaining sufficient follow-up time to ensure that treatment effects on HbA1c could be reliably estimated. Diagnoses were based on ICD codes, 12 but as EMR data may not link the actual diagnosis name, this could have resulted in some misclassifications.
Furthermore, T2D duration data were not available, so this could not be included in the matching process. Also, the reasons for the choice of basal insulin were not available in the EMRs, so selection bias may not be completely excluded, even after propensity score matching. It should also be remembered that EMRs only capture the prescription, not dispensing or consumption, of drugs. As dosage data were missing in~67% of the EMRs, detailed dose information could not be addressed in this study. However, we do not think that the absence of dose information from the patient matching process would have negatively affected the matching, as characteristics associated/correlated with dose were otherwise well matched (e.g. baseline HbA1c, body mass index, baseline concomitant medications).
Inpatient/ED hypoglycaemia should have been well captured in the EMR, but it is probable that many less serious events were not captured as there may not have been an accompanying healthcare claim. Lastly, although the study population represents a real-life US adult T2D population, the results may not be generalizable to the whole US population, as only 4% of patients were from the West or Northeast regions.
| Conclusions
Among previously insulin-naïve adults with T2D, under real-world circumstances, initiating Gla-300 or IDeg improved glycaemic control to a similar extent and both second-generation basal insulin analogues were associated with comparable levels of hypoglycaemia. These results from DELIVER Naive D complement the results from the first head-to-head RCT (BRIGHT trial) in insulin-naïve adults. 10 Moreover, they are fully consistent with data from other real-world studies in insulin-naïve or -experienced adults with T2D, 8, 9, 16 which all suggest that the two longer-acting basal insulins -Gla-300 and IDeg -have comparable effects in terms of efficacy, effectiveness, and hypoglycaemia outcomes. Overall, the results of our study add to the growing body of evidence that suggests that second-generation basal insulin analogues offer advantages over first-generation basal insulin analogues, and that use of either of these second-generation basal insulin analogues -Gla-300 or IDeg -represents an effective option for patients with T2D starting insulin.
